1. |
Cytokines: role in infectious diseases |
|
Inpharma Weekly,
Volume &NA;,
Issue 1345,
2002,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
2. |
Drug-eluting stents set to enter market |
|
Inpharma Weekly,
Volume &NA;,
Issue 1345,
2002,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
3. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1345,
2002,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
4. |
Capecitabine proves its worth in colorectal, breast cancer |
|
Inpharma Weekly,
Volume &NA;,
Issue 1345,
2002,
Page 5-6
Kimberley Salmon,
Preview
|
|
摘要:
The oral fluoropyrimidine agent capecitabine ['Xeloda'; Roche] has shown efficacy in the treatment of solid tumours, such as colorectal cancer and breast cancer. Capecitabine use is also associated with fewer adverse effects, and greater tolerability and efficacy, than other standard cancer therapies. However, newer antineoplastic therapies, such as capecitabine, tend to be more costly than older therapies, and studies that compare overall cost effectiveness of such drugs with older therapies are therefore of great interest to healthcare payers. At the 7th Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research [Arlington, Virginia, US; May 2002], two studies providing an economic evaluation of capecitabine were presented at sessions dedicated to cancer research.
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
5. |
Isoniazid programme to prevent TB cost effective in the US |
|
Inpharma Weekly,
Volume &NA;,
Issue 1345,
2002,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
6. |
Verteporfin worth it for age-related macular degeneration in the UK? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1345,
2002,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
7. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1345,
2002,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
8. |
Eplerenone shows advantages in hypertension |
|
Inpharma Weekly,
Volume &NA;,
Issue 1345,
2002,
Page 9-11
Raewyn Poole,
Preview
|
|
摘要:
Eplerenone, the first selective aldosterone receptor antagonist, is well tolerated and effective in the treatment of hypertension, particularly in Black patients and in those with low plasma renin levels, according to results from three phase III studies presented at the 17th Annual Scientific Meeting of the American Society of Hypertension (ASH) [New York, US; May 2002].*Furthermore, treatment with eplerenone may reduce the risk of end-organ damage by lowering urinary albumin/creatinine ratios (UACR). In two studies, eplerenone was significantly more effective than the angiotensin receptor antagonist losartan ['Cozaar'] in the treatment of hypertension in Black patients, and in those with low renin levels; these patient populations are typically difficult to treat with established antihypertensive agents, and have a higher risk of cardiovascular disease. In another pivotal study, eplerenone demonstrated equivalent efficacy to enalapril with respect to BP reduction, but provided greater reductions in UACR.
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
9. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1345,
2002,
Page 11-11
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
10. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1345,
2002,
Page 12-12
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|